These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37349129)
21. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802 [TBL] [Abstract][Full Text] [Related]
22. Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. Shin JM; Lee CH; Son S; Kim CH; Lee JA; Ko H; Shin S; Song SH; Park SS; Bae JH; Park JM; Choe EJ; Baek MC; Park JH Adv Sci (Weinh); 2022 Feb; 9(5):e2103245. PubMed ID: 34927389 [TBL] [Abstract][Full Text] [Related]
23. Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary. Sillah A; Tykodi SS; Hall ET; Thompson JA; Watson NF; Lee SM; Bhatia S; Veatch J; Warner J; Peters U; Malen RC; Silverman A; Phipps AI Future Oncol; 2021 Feb; 17(4):363-369. PubMed ID: 33397134 [TBL] [Abstract][Full Text] [Related]
24. Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade. Song E; Chow RD Cancer Cell; 2023 Apr; 41(4):651-652. PubMed ID: 36931275 [TBL] [Abstract][Full Text] [Related]
25. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338 [TBL] [Abstract][Full Text] [Related]
26. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature. Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818 [TBL] [Abstract][Full Text] [Related]
27. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614 [TBL] [Abstract][Full Text] [Related]
28. Infectious Complications of Immune Checkpoint Inhibitors. Abers MS; Lionakis MS Infect Dis Clin North Am; 2020 Jun; 34(2):235-243. PubMed ID: 32334989 [TBL] [Abstract][Full Text] [Related]
29. Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. Trigos AS; Pasam A; Banks P; Wallace R; Guo C; Keam S; Thorne H; ; Mitchell C; Lade S; Clouston D; Hakansson A; Liu Y; Blyth B; Murphy D; Lawrentschuk N; Bolton D; Moon D; Darcy P; Haupt Y; Williams SG; Castro E; Olmos D; Goode D; Neeson P; Sandhu S J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764368 [TBL] [Abstract][Full Text] [Related]
30. MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. Zhou Y; Tan Y; Zhang Q; Duan Q; Chen J Eur J Med Res; 2022 Oct; 27(1):225. PubMed ID: 36309740 [TBL] [Abstract][Full Text] [Related]
31. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B Front Immunol; 2020; 11():1956. PubMed ID: 32983126 [TBL] [Abstract][Full Text] [Related]
36. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. Goncalves A; Mezni E; Bertucci F Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311 [TBL] [Abstract][Full Text] [Related]
37. NLRC5/CITA: A Key Player in Cancer Immune Surveillance. Yoshihama S; Vijayan S; Sidiq T; Kobayashi KS Trends Cancer; 2017 Jan; 3(1):28-38. PubMed ID: 28718425 [TBL] [Abstract][Full Text] [Related]
38. Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Li Y; Wang S; Lin M; Hou C; Li C; Li G Front Med; 2022 Jun; 16(3):307-321. PubMed ID: 35648368 [TBL] [Abstract][Full Text] [Related]
39. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. Ahn R; Ursini-Siegel J Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608 [TBL] [Abstract][Full Text] [Related]
40. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers. Ong CEB; Patchett AL; Darby JM; Chen J; Liu GS; Lyons AB; Woods GM; Flies AS J Cancer Res Clin Oncol; 2021 Jul; 147(7):1973-1991. PubMed ID: 33797607 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]